Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/7/2018
SIETES contiene 92427 citas

 
 
 1 a 20 de 2569 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Montané E, Arellano AL, Sanz Y, Roca J, Farré M. Drug-related deaths in hospital inpatients: A retrospective cohort study. Br J Clin Pharmacol 2018;84:marzo. [Ref.ID 102649]
2.Enlace a cita original Cita con resumen
Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular outcomes with proton pump inhibitors and thienopyridines. Stroke 2018;49:febrero. [Ref.ID 102619]
3.Enlace a cita original Cita con resumen
Lembke A, Papac J, Humphreys K. Our other prescription drug problem. N Engl J Med 2018;378:22 de febrero. [Ref.ID 102557]
4. Cita con resumen
Anónimo. Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone. European Medical Agency 2018:1. [Ref.ID 102552]
5.Enlace a cita original Cita con resumen
Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]
8.Enlace a cita original Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 rhrough 2015. JAMA Intern Med 2018;178:febrero. [Ref.ID 102530]
9. Cita con resumen
Herzig SJ, Mosher HJ, Calcaterra SL, Jena AB, Nuckols TK. Improving the safety of opioid use for acute noncancer pain in hospitalized adults: a consensus statement from the Society of Hospital Medicine. J Hosp Med 2018;13:abril. [Ref.ID 102501]
10. Cita con resumen
Johansen ME. Gabapentinoid use in the United States 2002 through 2015. JAMA Intern Med 2018:2 de enero. [Ref.ID 102440]
12. Cita con resumen
Peckham AM, Fairman KA, Sclar DA. Call for increased pharmacovigilance of gabapentin. BMJ 2017;359:j5456. [Ref.ID 102156]
13. Cita con resumen
Brett J, Daniels B, Karanges EA, Buckley NA, Schneider C, Nassir A, McLachlan AJ, Pearson S-A. Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study. Br J Clin Pharmacol 2017;83:2581-8. [Ref.ID 102118]
14. Cita con resumen
Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study. PLOS Medicine 2017:3 de octubre. [Ref.ID 102112]
15. Cita con resumen
Bakhriansyah M, Souverein PC, de Boer A, Klungel OH. Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study. Pharmacoepidemiol Drug Saf 2017;26:1141-8. [Ref.ID 102084]
16. Cita con resumen
Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]
17. Cita con resumen
Chang S-H, Chou I-J, Yeh Y-H, Chiou M-J, Wen M-S, Kuo C-T, See L-C, Kuo C-F. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA 2017;318:1250-9. [Ref.ID 102073]
19. Cita con resumen
Buttram ME, Kurtz SP, Dart RC, Margolin ZR. Law enforcement-derived data on gabapentin diversion and misuse, 2002-2015: diversion rates and qualitative research findings. Pharmacoepidemiol Drug Saf 2017;26:1083-7. [Ref.ID 102063]
20.Tiene citas relacionadas Cita con resumen
Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;377:699-700. [Ref.ID 102019]
Seleccionar todas
 
 1 a 20 de 2569 siguiente >>